Proactive Investors - Run By Investors For Investors

MedLab Clinical plans European product expansion with wholly-owned subsidiary

Medlab Clinical Ltd (ASX:MDC) managing director & CEO Sean Hall speaks to Proactive Investors about the pharmaceutical company’s new European subsidiary and its development of products to treat chronic disease.

Medlab has 30 nutraceutical products (pharmaceutical-grade and standardised nutrients) globally, with another 10 in development, and two cannabis-based medicines NanaBis and NanaBidial which contain formulations of tetrahydrocannabinol and cannabidiol.

“There are financial advantages and concessions potentially available with the European Medicines Agency (EMA), if there is a European subsidiary,” Hall says.

He continues, “we are now exchanging paperwork with the EMA and trying to formalise what could be a significant discount on their drug registration fees moving forward, so that we can move beyond pathway development and actually formalising it with the regulatory agency for approved claims in Europe.”

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here  
Meet Cardinal Resources Ltd and Legend Mining Ltd at our event, Melbourne , 16 July 2019. Register here »
View full MDC profile View Profile

Medlab Clinical Ltd Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use